The Sculptique Aesthetics
MOTS-c: A Mitochondrial Peptide, Metabolism Research, and the Weight-Loss Hype
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Mice and blood-level studies are not a weight-loss treatment. A registered trial without results is not proof.

MOTS-c shows up in the same feeds as Mounjaro. One is a mitochondrial peptide with early research. The other is a medicine with large trials. I will not let the feed flatten that.
— Dr. Aamod Rao
MOTS-c is a peptide of 16 amino acids. The name is a description of where the code sits: mitochondrial open reading frame of the 12S rRNA type-c. It is made from mitochondrial DNA, not from the usual nuclear genes, and cells can release it into the blood, where it behaves a little like a hormone. It was reported in 2015 as a signal involved in metabolic stress.
That is a genuine piece of biology. It became, a decade later, a vial in the same shopping cart as injury peptides and weight-loss injections. Those are different claims.
What the animal work showed
In mice, giving MOTS-c has been reported to improve insulin sensitivity and to blunt weight gain and high insulin on a high-fat diet. AMPK, a fuel-sensing pathway in muscle, is the mechanism most often named. Muscle is a sensible place to look. It is where a large share of glucose is handled.
Mouse results are how this field starts. They are not a prescription, a human dose, or a promise that the same injection will change a person's weight, waist or HbA1c.
What human studies have actually done
Most human papers do not inject MOTS-c. They measure the MOTS-c people already have in their blood.
One well-known example found that plasma levels were similar in a small group of lean and obese adults, and that the relationship with insulin-sensitivity measures showed up in the lean group. A later study found higher circulating MOTS-c in adults with obesity, a complicated relationship with insulin resistance, and no drop in those levels six months after bariatric surgery despite the weight loss. Read together, they say the body's own MOTS-c moves with metabolic state in ways that are not simple. They do not say that buying MOTS-c and injecting it reproduces the healthy pattern.
Measuring a hormone is not the same experiment as giving it. A higher or lower level in obesity does not tell you the direction of treatment. It does not even tell you that the level is the cause.
A randomised Phase 2a trial of investigational MOTS-c in adults with prediabetes and overweight or obesity has been registered (NCT07505745), looking at insulin sensitivity over 12 weeks against placebo. Registration means the question is being asked properly. It does not mean the answer is yes. Until results are posted, "improves insulin sensitivity" is the hypothesis in the protocol, not a finding. US compounding reviewers, looking at products already being sold, have at the same time been able to say that clinical evidence for those products is thin. A registry record and a thin evidence file can both be true.
In July 2026, MOTS-c was among the peptides a US advisory committee discussed for possible compounding. That vote is not an approval, not a weight-loss licence, and not a standard dose.
What this is not a substitute for
Semaglutide and tirzepatide have large human trials for weight and, for some indications, for diabetes. MOTS-c does not. How those medicines differ and what happens to skin after a large loss are separate articles. So is the question of muscle loss while the scale is moving.
NAD+ is the other name that gets filed under "cellular energy." NAD+ is a coenzyme, not a peptide. Our NAD+ pages are about that coenzyme. They are not a back door to MOTS-c.
If your goal is fat loss, the conversation in this clinic is about medicines that have trials, about protein and training while you lose, and about the face and skin afterwards. It is not about an unapproved mitochondrial peptide as a quieter alternative. If your goal is skin, MOTS-c is not a skin drug. Peptide therapy that we do use is chosen for a reason we can explain.
Frequently asked questions
A 16-amino-acid peptide encoded in mitochondrial DNA and released as a metabolic signal. It is not an approved weight-loss or diabetes medicine.
Published treatment trials have not established that. The famous findings are in mice. Human papers have mostly measured natural blood levels, which is a different experiment.
No. A Phase 2a study can be recruiting and still have nothing to report. The result is the result. The registration is a plan.
No. Advisory votes in 2026 did not create efficacy, safety, or a dose. They do not set Indian practice either.
There is no basis for that swap. Muscle and nutrition on semaglutide or tirzepatide are handled with training, protein and the prescribing doctor, not with an experimental peptide from a reel.
Bring the goal, not the acronym
Tell us whether you want metabolic care, skin, or an explanation of a vial you were sold. Those are three different visits. We will not collapse them into one injection because the peptide is having a moment.
Book a consultation · Peptide therapy
Sources
Checked 18 November 2026:
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. Mouse and mechanistic work, not a human treatment trial.
- Plasma MOTS-c and insulin sensitivity in lean versus obese adults, a measurement study. https://pubmed.ncbi.nlm.nih.gov/29593067/
- Circulating MOTS-c in adults with obesity, including levels after bariatric surgery. Measurement, not administration. https://pmc.ncbi.nlm.nih.gov/articles/PMC12807633/
- Phase 2a randomised trial, registered, results not a finding until posted: NCT07505745. https://clinicaltrials.gov/study/NCT07505745
- July 2026 advisory discussion, including MOTS-c. Not an approval. https://www.healthed.com.au/clinical_articles/peptide-use-in-australia-what-gps-need-to-know/
This article is for educational purposes only. It is not medical advice and does not replace a consultation with a qualified clinician.








